Cencora, formerly known as AmerisourceBergen, is one of the Big 3 drug distributors alongside peers McKesson Corporation (MCK) and Cardinal Health, Inc. (CAH). It provides pharmaceutical ...

Baird raised the firm’s price target on Cencora (COR) to $307 from $305 and keeps an Outperform rating on the shares. The firm noted it was another beat and raise quarter. Published first on ...

Wells Fargo raised the firm’s price target on Cencora (COR) to $274 from $251 and keeps an Equal Weight rating on the shares. The firm is updating its model following Cencora’s results and ...

Cencora (NYSE:COR) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table ...

In this article, we are going to take a look at where Cencora, Inc. (NYSE:COR) stands against other stocks with at least $30 million in insider sales recently. Last week, stocks declined in part ...

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments.

Have you been paying attention to shares of Cencora (COR)? Shares have been on the move with the stock up 6.2% over the past month. The stock hit a new 52-week high of $262.56 in the previous session.

Ahead of the event, analysts expect Cencora to report a profit of $3.50 per share, up 6.7% from $3.28 in the year-ago quarter.The company has consistently surpassed Wall Street’s adjusted EPS ...

It has been about a month since the last earnings report for Cencora (COR). Shares have added about 3.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...